
Inocras Unveils ASCO 2026 Findings on Whole-Genome HRD Phenotyping to Predict PARP Inhibitor Response in Ovarian Cancer
Inocras Presents Real-World Evidence Supporting Whole-Genome HRD Profiling in Ovarian Cancer Treatment Inocras, a bioinformatics-driven precision oncology company specializing in whole-genome sequencing and advanced genomic analytics, has announced that new…












